What are the CANDOR and MMY1001 studies?
The CANDOR trial is a randomized phase III study that compares the efficacy of Kyprolis (carfilzomib), dexamethasone, and Darzalex (daratumumab) (KdD) to Kyprolis and dexamethasone alone (Kd) in relapsed refractory multiple myeloma patients. MMY1001 is a nonrandomized study of the benefit of once-weekly carfilzomib (K) at 70 mg/m2 for the same triplet, KdD. 

In this video:
Dr. Xavier Leleu explains this robust cross-study comparison to investigate twice-weekly KdD at 56 mg/mcompared to once-weekly KdD at 70 mg/m2. The primary analysis set for this cross-study comparison included individual data from CANDOR patients with prior exposure to Velcade (bortezomib) and immunomodulatory drug, and all patients in MMY1001. A stringent statistical analysis (the propensity scoring method) was used to determine efficacy endpoints. Safety, however, was evaluated side-by-side.

The results:
The CANDOR trial showed significantly improved progression-free survival (PFS) and overall response rate (ORR) for twice-weekly KdD 56 mg/m2 versus Kd in relapsed refractory multiple myeloma with a 37% risk reduction in disease progression or death.

The benefit of once-weekly carfilzomib (K) at 70 mg/m2 for the same triplet, KdD in relapsed refractory multiple myeloma was favorable as compared to twice-weekly dosing 56 mg/m2. 

Once-weekly KdD at 70 mg/mis an efficacious dosing option with favorable benefit-risk, comparable to twice-weekly dosing 56 mg/m2. The once-weekly KdD at 70 mg/mdosing option represents a more convenient regimen that might encourage adherence and potentially lead to better outcomes for relapsed refractory multiple myeloma patients. 

Clinical trial information: NCT03158688


Dr. Xavier Leleu is the Head of the Myeloma Clinic and Head of the Department of Hematology at Hôpital La Mileterie, part of the academic hospital of Poitiers, France. He is actively involved in numerous national and international clinical trials as an investigator and coordinator. Dr. Leleu is a frequent speaker at national and international congresses and is a reviewer or a member of the editorial board of several hematology journals. He is actively involved in the Intergroupe Francophone du Myélome. 


Previous Post
Clinical implications of loss of minimal residual disease (MRD) negativity in multiple myeloma
Next Post
Results of ENDURANCE (E1A11) phase III trial: KRd versus VRd for initial therapy of NDMM

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.